KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Enterprise Value (2016 - 2025)

Pfizer (PFE) has disclosed Enterprise Value for 17 consecutive years, with $299.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 101.48% to $299.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $299.0 million, a 101.48% increase, with the full-year FY2025 number at $299.0 million, up 101.48% from a year prior.
  • Enterprise Value was $299.0 million for Q4 2025 at Pfizer, up from -$14.7 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of $299.0 million in Q4 2025 to a low of -$30.8 billion in Q4 2021.
  • A 5-year average of -$5.9 billion and a median of -$2.0 billion in 2021 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: plummeted 7660.0% in 2023, then surged 101.48% in 2025.
  • Pfizer's Enterprise Value stood at -$30.8 billion in 2021, then surged by 99.48% to -$160.0 million in 2022, then tumbled by 7660.0% to -$12.4 billion in 2023, then crashed by 62.56% to -$20.2 billion in 2024, then surged by 101.48% to $299.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Enterprise Value are $299.0 million (Q4 2025), -$14.7 billion (Q3 2025), and -$1.3 billion (Q2 2025).